Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
UAE recalls some Nestle infant formula products, Qatar warns consumers- Grass Care Administrations for a Wonderful, Sound Yard
- Why don’t humans have hair all over their bodies? A biologist explains our lack of fur
- Audits of the Top Science fiction Movies This Year
- Vote In favor of Your Number one Sort Of Blossoms
- 5 Great Home Remodel Administrations With Green Arrangements In 2024
- Pick Your #1 game to observe
- Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- What's the Fate of 5G Innovation?
